Therefore, integrating RDW with APACHE II and additional biomarkers (PCT, IL-6, CRP, and Cystatin C) may enhance the predictive accuracy of AKI risk assessment, providing clinicians with a more comprehensive decision-making tool. This evidence concerns the gene IL6 and acute kidney injury.